Abstract
Epithelial ovarian cancers (EOCs) arise in the Ovarian Surface Epithelium (OSE). This tissue is a simple, poorly committed mesothelium which exhibits characteristics of epithelial and mesenchymal cells when grown in culture. In contrast, EOCs frequently exhibit properties of complex epithelial tissues of the female reproductive tract, such as oviductal, endometrial and cervical epithelia, and show induction of expression of epithelial markers such as E-cadherin. Fibroblast Growth Factor Receptor 2 isoform IIIb (FGF receptor 2-IIIb) is a spliced variant of FGF receptor 2 that binds the ligands FGF-1 and FGF-7 with high affinity, and is expressed exclusively by epithelial cells. We have studied the expression of FGF receptor 2-IIIb and its ligands in primary cultures of normal human OSE, EOC cell lines and snap frozen tissue from EOCs. Expression of FGF receptor 2-IIIb mRNA is undetectable in normal OSE, but is expressed in 16/20 (80%) of EOCs. FGFs 1 and 7 mRNAs are expressed in normal OSE, whilst only 4/20 (20%) and 12/20 (60%) of EOCs demonstrated expression for these ligands respectively. However, FGF-7 protein was detected in 70% (mean level = 0.7 ng/ml) of ascitic fluids obtained from patients with EOC. FGFs 1 and 7 stimulate DNA synthesis in EOC cell lines that express FGF receptor 2-IIIb. Moreover, DNA synthesis in these cell lines can be partially blocked by blocking antisera to FGFs 1 and 7. It is suggested that induction of expression of FGF receptor 2-IIIb may play a role in the development of EOCs by rendering the OSE susceptible to paracrine and/or autocrine stimulation by its requisite FGF ligands.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD . 1999 Proc. Natl. Acad. Sci. USA 96: 6249–6254
Basilico C, Moscatelli D . 1992 Adv. Cancer Res. 59: 115–165
Bast Jr RC, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A . 1995 J. Cell. Biochem. Suppl. 23: 219–222
Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast Jr RC . 1993 Cancer 71: 545–551
Burgess WH, Maciag T . 1989 Annu. Rev. Biochem. 58: 575–606
Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, Eidsvoog K . 1994 Gynecol. Oncol. 55: 277–284
Davies BR, Worsley SD, Ponder BA . 1998 Histopathology 32: 69–80
De Medina SG-D, Popov Z, Chopin DK, Southgate J, Tucker GC, Delouvee A, Thiery JP, Radvanyi F . 1999 Oncogene 18: 5722–5726
Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB . 1993 Am. J. Obstet. Gynecol. 169: 1517–1523
Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N . 1996 Int. J. Cancer 69: 429–436
Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA . 1989 Science 245: 752–755
Friesel RE, Maciag T . 1995 FASEB J. 9: 919–925
Givol D, Yayon A . 1992 FASEB J. 6: 3362–3369
Hernandez E, Rosenheim NB . 1989 Manual of Gynecologic Oncology Churchill Livingstone: London pp 57–74
Inoue M, Ogawa H, Miyata M, Shiozaki H, Tanizawa O . 1992 Am. J. Clin. Pathol. 98: 76–80
Klug TL, Bast Jr RC, Niloff JM, Knapp RC, Zurawski Jr VR . 1984 Cancer Res. 44: 1048–1053
Kruk PA, Maines-Bandiera SL, Auersperg N . 1990 Lab. Invest. 63: 132–136
Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N . 1994 Exp. Cell. Res. 215: 97–108
Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE . 1997 Oncogene. 15: 1115–1120
Lu W, Luo Y, Kan M, McKeehan WL . 1999 J. Biol. Chem. 274: 12827–12834
Maines-Bandiera SL, Auersperg N . 1997 Int. J. Gynecol. Pathol. 16: 250–255
Mason IJ . 1994 Cell 78: 547–552
Mehta PB, Robson CN, Neal DE, Leung HY . 2000 J. Urol. 164: 2151–2155
Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA . 1992 Proc. Natl. Acad. Sci. USA 89: 246–250
Ong A, Maines-Bandiera SL, Roskelley CD, Auersperg N . 2000 Int. J. Cancer 85: 430–437
Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P . 1993 Dev. Biol. 158: 475–486
Parrott JA, Vigne JL, Chu BZ, Skinner MK . 1994 Endocrinology 135: 569–575
Peters KG, Werner S, Chen G, Williams LT . 1992 Development 114: 233–243
Resta L, Russo S, Colucci GA, Prat J . 1993 Obstet. Gynecol. 82: 181–186
Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA . 1989 Proc. Natl. Acad. Sci. USA 86: 802–806
Scully RE . 1977 Am. J. Pathol. 87: 686–720
Scully RE . 1992 Ovarian Cancer 2: Biology, diagnosis, management Chapman and Hall: London pp 199–205
Scully RE . 1995 J. Cell. Biochem. Suppl. 23: 208–218
Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L . 1997 Int. J. Cancer 74: 275–280
Veatch AL, Carson LF, Ramakrishnan S . 1994 Int. J. Cancer 58: 393–399
Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S . 1997 Cancer Treat. Rev. 23: 113–131
Yamashita T, Yoshioka M, Itoh N . 2000 Biochem. Biophys. Res. Commun. 277: 494–498
Young RH, Clement PB, Scully RE . 1989 Diagnostic and Surgical Pathology Sternberg, SS. (ed.) Raven Press: New York pp 1655–1734
Acknowledgements
We would like to thank Dr Anne Wilson (Oncology Research Laboratory, Derby, UK) for providing some of the ovarian cancer ascitic fluid and Mrs Barbara Innes for technical assistance with the E-cadherin immunocytochemistry. This work was supported by a William Ross PhD studentship from the Cancer Research Campaign (CRC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Steele, I., Edmondson, R., Bulmer, J. et al. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 20, 5878–5887 (2001). https://doi.org/10.1038/sj.onc.1204755
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204755
Keywords
This article is cited by
-
Sialyl Lewisx-P-selectin cascade mediates tumor–mesothelial adhesion in ascitic fluid shear flow
Nature Communications (2019)
-
Investigational agents in development for the treatment of ovarian cancer
Investigational New Drugs (2013)
-
P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin
Oncogene (2011)
-
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases
Breast Cancer Research (2007)
-
Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2
Oncogene (2004)